Zydus introduces cancer treatment IBYRA in India, making advanced therapy accessible

Zydus introduces cancer treatment IBYRA in India, making advanced therapy accessible

In a groundbreaking development for cancer treatment in India, Zydus Lifesciences has launched Olaparib under the brand name IBYRA, a pioneering PARP inhibitor designed to target specific genetic mutations. This strategic move aims to provide a more personalized and effective approach to combating various types of cancers, including breast, ovarian, prostate, and pancreatic cancers, which […]

Torrent Pharmaceuticals to co-market Saroglitazar Mg with Zydus for liver health

Torrent Pharmaceuticals to co-market Saroglitazar Mg with Zydus for liver health

Torrent Pharmaceuticals Limited and Zydus Lifesciences Limited announced a significant licensing and supply agreement to co-market Saroglitazar Mg, a drug for treating Non-Alcoholic Steato Hepatitis (NASH) and Non-Alcoholic Fatty Liver Disease (NAFLD) in India. As the only drug approved in the country for these liver disorders, Saroglitazar Magnesium is poised to play a crucial role […]

FDA approves ZITUVIMET by Zydus Lifesciences for Type 2 diabetes treatment

FDA approves ZITUVIMET by Zydus Lifesciences for Type 2 diabetes treatment

Zydus Lifesciences Limited has achieved a significant milestone with the U.S. Food and Drug Administration (FDA) granting approval for ZITUVIMET, a combination of Sitagliptin and Metformin hydrochloride, designed to improve glycemic control in adults with type 2 diabetes mellitus as part of a comprehensive lifestyle intervention. ZITUVIMET: A New Adjunct in Diabetes Care With the […]

Zydus and Lupin forge alliance for NAFLD and NASH treatment in India

Zydus and Lupin forge alliance for NAFLD and NASH treatment in India

In a significant move within the pharmaceutical industry, Zydus Lifesciences Limited, renowned for its global lifesciences innovations, and Lupin Limited, a leading global pharma entity, have officially declared their collaboration. The two companies have established a licensing and supply agreement for the co-marketing of Saroglitazar Mg, a pivotal medication for the management of Non-Alcoholic Fatty […]

FDA approves Zydus Lifesciences’ ZITUVIO tablets for Type 2 diabetes

FDA approves Zydus Lifesciences’ ZITUVIO tablets for Type 2 diabetes

Zydus Lifesciences Limited announced today that the U.S. Food and Drug Administration (FDA) has granted approval for its New Drug Application (NDA) for ZITUVIO (Sitagliptin) tablets in three dosages: 25 mg, 50 mg, and 100 mg. What is ZITUVIO? Containing the active ingredient Sitagliptin, ZITUVIO functions as a dipeptidyl peptidase-4 (DPP-4) inhibitor. It’s specifically designed […]

Zydus Lifesciences announces Punit Patel as new CEO for Americas operations

Zydus Lifesciences announces Punit Patel as new CEO for Americas operations

Global lifesciences firm, Zydus Lifesciences Limited, recently declared the appointment of Punit Patel as the President and Chief Executive Officer for its Americas wing. He’s set to head the conglomerate’s business in North America, covering a spectrum from generics and injectables to novel therapeutics. This pivotal move emanates from Zydus’s base in Pennington, New Jersey. […]

Zydus Lifesciences to commercialize OncoStem’s CanAssist Breast test

Zydus Lifesciences to commercialize OncoStem’s CanAssist Breast test

Zydus Lifesciences has secured exclusive marketing rights to CanAssist Breast, a prognostic test for breast cancer patients in the early stages, from Bengaluru-based OncoStem. According to Zydus Lifesciences, CanAssist Breast will enable clinicians in taking a call if the patient requires chemotherapy or not. By leveraging OncoStem’s proprietary artificial intelligence/machine learning methods, CanAssist Breast can […]